Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Share
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Matt Bryson of Wedbush Securities joins ‘TechCheck’ to discuss the swelling supply of semiconductors, bullish picks for the chip sector and the outlook for chip providers in gaming. 04:32 Tue, Dec 27 202212:08 PM EST
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Anthony Pompliano, Pomp Investment founder and partner, joins ‘Squawk Box’ to discuss the SEC’s approval of spot bitcoin ETFs, what it means for investors and the crypto community at large, and more. 09:47 Thu, Jan 11 20248:00 AM EST
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Bitcoin ETFs begin trading, with several of them already in the red. CNBC’s Bob Pisani joins us with Bitwise Asset Management CIO Matt Hogan to discuss the sector. The Investment Committee also debates their top picks in the sector.
© 2024 CNBC LLC. All Rights Reserved. A Division of NBCUniversal Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Market Data Terms of Use and Disclaimers Data also provided by
Internet lingerie startup “Adore Me” aims to disrupt the U.S. lingerie market. One strategy their using, is to crowdsource the designs they bring to market.
CNBC’s Eamon Javers joins ‘Power Lunch’ to discuss the SEC and X investigating a fake SEC post.